Hemolytic disease of the newborn (anti-Kell): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 18: Line 18:
The disease results when maternal [[antibodies]] to Kell<sub>1</sub> are transferred to the fetus across the [[placenta|placental barrier]]. These antibodies can cause severe [[anemia]] by interfering with the early proliferation of [[red blood cells]] as well as causing [[alloimmune]] hemolysis.  Very severe disease can occur as early as 20 weeks gestation.  [[Hydrops fetalis]] can also occur early.  The finding of anti-Kell antibodies in an antenatal screening blood test ([[coombs test#indirect coombs test|indirect Coombs test]]) is an indication for early referral to a specialist service for assessment, management and treatment.   
The disease results when maternal [[antibodies]] to Kell<sub>1</sub> are transferred to the fetus across the [[placenta|placental barrier]]. These antibodies can cause severe [[anemia]] by interfering with the early proliferation of [[red blood cells]] as well as causing [[alloimmune]] hemolysis.  Very severe disease can occur as early as 20 weeks gestation.  [[Hydrops fetalis]] can also occur early.  The finding of anti-Kell antibodies in an antenatal screening blood test ([[coombs test#indirect coombs test|indirect Coombs test]]) is an indication for early referral to a specialist service for assessment, management and treatment.   


===anti-Kell<sub>2</sub>, anti-Kell<sub>3</sub> and anti-Kell<sub>4</sub> antibodies===
===Anti-Kell<sub>2</sub>, anti-Kell<sub>3</sub> and anti-Kell<sub>4</sub> antibodies===


Hemolytic disease of the newborn can also be caused by anti-Kell<sub>2</sub>, anti-Kell<sub>3</sub> and anti-Kell<sub>4</sub> IgG antibodies.  These are rarer and generally the disease is milder.
Hemolytic disease of the newborn can also be caused by anti-Kell<sub>2</sub>, anti-Kell<sub>3</sub> and anti-Kell<sub>4</sub> IgG antibodies.  These are rarer and generally the disease is milder.


==Cause==
==Causes==
Mothers who are negative for the Kell<sub>1</sub> antigen develop antibodies after being exposed to red blood cells that are positive for Kell<sub>1</sub>.  Over half of the cases of hemolytic disease of the newborn owing the anti-Kell antibodies are caused by multiple blood transfusions, with the remainder due to a previous pregnancy with a Kell<sub>1</sub> positive baby.
Mothers who are negative for the Kell<sub>1</sub> antigen develop antibodies after being exposed to red blood cells that are positive for Kell<sub>1</sub>.  Over half of the cases of hemolytic disease of the newborn owing the anti-Kell antibodies are caused by multiple blood transfusions, with the remainder due to a previous pregnancy with a Kell<sub>1</sub> positive baby.


Line 34: Line 34:


==References==
==References==
{{Reflist|2}}
*Geifman-Holtzman O, Wojtowycz M, Kosmas E, and Artal R.  Female allo-immunization with antibodies known to cause hemolytic disease.  Obstetrics and Gynecology 1997  89, 272-275
*Geifman-Holtzman O, Wojtowycz M, Kosmas E, and Artal R.  Female allo-immunization with antibodies known to cause hemolytic disease.  Obstetrics and Gynecology 1997  89, 272-275



Revision as of 13:32, 21 September 2012

Template:DiseaseDisorder infobox

WikiDoc Resources for Hemolytic disease of the newborn (anti-Kell)

Articles

Most recent articles on Hemolytic disease of the newborn (anti-Kell)

Most cited articles on Hemolytic disease of the newborn (anti-Kell)

Review articles on Hemolytic disease of the newborn (anti-Kell)

Articles on Hemolytic disease of the newborn (anti-Kell) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hemolytic disease of the newborn (anti-Kell)

Images of Hemolytic disease of the newborn (anti-Kell)

Photos of Hemolytic disease of the newborn (anti-Kell)

Podcasts & MP3s on Hemolytic disease of the newborn (anti-Kell)

Videos on Hemolytic disease of the newborn (anti-Kell)

Evidence Based Medicine

Cochrane Collaboration on Hemolytic disease of the newborn (anti-Kell)

Bandolier on Hemolytic disease of the newborn (anti-Kell)

TRIP on Hemolytic disease of the newborn (anti-Kell)

Clinical Trials

Ongoing Trials on Hemolytic disease of the newborn (anti-Kell) at Clinical Trials.gov

Trial results on Hemolytic disease of the newborn (anti-Kell)

Clinical Trials on Hemolytic disease of the newborn (anti-Kell) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hemolytic disease of the newborn (anti-Kell)

NICE Guidance on Hemolytic disease of the newborn (anti-Kell)

NHS PRODIGY Guidance

FDA on Hemolytic disease of the newborn (anti-Kell)

CDC on Hemolytic disease of the newborn (anti-Kell)

Books

Books on Hemolytic disease of the newborn (anti-Kell)

News

Hemolytic disease of the newborn (anti-Kell) in the news

Be alerted to news on Hemolytic disease of the newborn (anti-Kell)

News trends on Hemolytic disease of the newborn (anti-Kell)

Commentary

Blogs on Hemolytic disease of the newborn (anti-Kell)

Definitions

Definitions of Hemolytic disease of the newborn (anti-Kell)

Patient Resources / Community

Patient resources on Hemolytic disease of the newborn (anti-Kell)

Discussion groups on Hemolytic disease of the newborn (anti-Kell)

Patient Handouts on Hemolytic disease of the newborn (anti-Kell)

Directions to Hospitals Treating Hemolytic disease of the newborn (anti-Kell)

Risk calculators and risk factors for Hemolytic disease of the newborn (anti-Kell)

Healthcare Provider Resources

Symptoms of Hemolytic disease of the newborn (anti-Kell)

Causes & Risk Factors for Hemolytic disease of the newborn (anti-Kell)

Diagnostic studies for Hemolytic disease of the newborn (anti-Kell)

Treatment of Hemolytic disease of the newborn (anti-Kell)

Continuing Medical Education (CME)

CME Programs on Hemolytic disease of the newborn (anti-Kell)

International

Hemolytic disease of the newborn (anti-Kell) en Espanol

Hemolytic disease of the newborn (anti-Kell) en Francais

Business

Hemolytic disease of the newborn (anti-Kell) in the Marketplace

Patents on Hemolytic disease of the newborn (anti-Kell)

Experimental / Informatics

List of terms related to Hemolytic disease of the newborn (anti-Kell)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Anti-Kell1

Overview

Hemolytic disease of the newborn is the second most common cause of severe hemolytic diseases of newborns (HDN) after Rh disease. Anti-Kell1 is becoming relatively more important as prevention of Rh disease is becoming more and more effective.

Pathophysiology

Hemolytic disease of the newborn (anti-Kell1 is caused by a mis-match between the Kell antigens of the mother and fetus. About 91% of the population are Kell1 negative and about 9% are Kell1 positive. A fraction of a percentage are homozygous for Kell 1. Therefore, about 4.5% of babies of a Kell1 negative mother are Kell1 positive.

The disease results when maternal antibodies to Kell1 are transferred to the fetus across the placental barrier. These antibodies can cause severe anemia by interfering with the early proliferation of red blood cells as well as causing alloimmune hemolysis. Very severe disease can occur as early as 20 weeks gestation. Hydrops fetalis can also occur early. The finding of anti-Kell antibodies in an antenatal screening blood test (indirect Coombs test) is an indication for early referral to a specialist service for assessment, management and treatment.

Anti-Kell2, anti-Kell3 and anti-Kell4 antibodies

Hemolytic disease of the newborn can also be caused by anti-Kell2, anti-Kell3 and anti-Kell4 IgG antibodies. These are rarer and generally the disease is milder.

Causes

Mothers who are negative for the Kell1 antigen develop antibodies after being exposed to red blood cells that are positive for Kell1. Over half of the cases of hemolytic disease of the newborn owing the anti-Kell antibodies are caused by multiple blood transfusions, with the remainder due to a previous pregnancy with a Kell1 positive baby.

Medical Therapy

It can be detected by routine antenatal antibody screening blood tests (indirect Coombs test) in a similar way to Rh disease. The treatment of hemolytic disease of the newborn (anti-Rhc) is similar to the management of Rh disease.

Primary Prevention

Suggestions have been made that women of child bearing age or young girls should not be given a transfusion with Kell1 positive blood. Donated blood is not currently screened (in the U.S.A.) for the Kell blood group antigens as it is not considered cost effective at this time.

It has been hypothesized that IgG anti-Kell1 antibody injections would prevent sensitization to RBC surface Kell1 antigens in a similar way that IgG anti-D antibodies (Rho(D) Immune Globulin) are used to prevent Rh disease, but the methods for IgG anti-Kell 1 antbodies have not been developed at the present time.

References

  • Geifman-Holtzman O, Wojtowycz M, Kosmas E, and Artal R. Female allo-immunization with antibodies known to cause hemolytic disease. Obstetrics and Gynecology 1997 89, 272-275
  • Wiener CP, and Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. American Journal of Obstetrics and Gynecology. 1996 174: 547-55

Related Chapters

Template:HDN


Template:WikiDoc Sources